Clinical Trials Sponsored by Fondazione Italiana Sindromi Mielodisplastiche-ETS

Total 42 results

Fondazione Italiana Sindromi Mielodisplastiche-ETS

Recruiting

Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care (FISiM-NGS-MDS)

MDS (Myelodysplastic Syndrome)

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Completed

Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy (BIOFER12)

Myelofibrosis | Aplastic Anemia | Myelodysplasia

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Withdrawn

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes (CLO2009AISSM05)

Myelodysplastic Syndromes

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Recruiting

Italian Network MDS Registry (FISM_registry)

Myelodysplastic-Myeloproliferative Diseases

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Terminated

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Myelodysplastic Syndromes

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Istituto Clinico Humanitas

Completed

Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche (FISiM-Luspa)

Myeloid Dysplasia

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes

Myelodysplastic Syndromes

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Completed

Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia (DECI2009)

Chronic Myelomonocytic Leukemia

Italy
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Myelodysplastic Syndromes

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Primary Cardiac Lymphoma: Italian Multicenter Experience

Primary Cardiac Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial (FIL_FOLL-BIO)

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma

Low Grade Non-Hodgkin's Lymphoma, Adult

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell

Lymphoma | Large B-Cell | Diffuse Large B-Cell

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial (FIL-RougeBIO)

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma (FIL_MOGA)

Cutaneous T Cell Lymphoma | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Cutaneous T-Cell Lymphoma/Sezary Syndrome

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance (FIL_FollVax22)

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy (FIL_Tisle-HL)

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (FIL_BIOWM)

Waldenstrom Macroglobulinemia

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Relapsed Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Terminated

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

T-Cell Lymphoma Relapsed | T-Cell Lymphoma Refractory

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (FIL_PTCL13)

Peripheral T-cell Lymphomas (PTCL) | PTCL-NOS | Angioimmunoblastic T-cell Lymphoma (AITL) | ALK- Anaplastic Large Cell Lymphoma (ALCL) | Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

Lymphoma, Follicular

Italy
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Classical Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Large B Cell Lymphoma (DLBCL)

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN)

Refractory Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

The Role of 18F-FDG-PET for Staging and Prognostication

Mantle Cell Lymphoma

Portugal, Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Indolent Non Follicular Lymphomas Prognostic Project

Indolent B-Cell Lymphomas

France, Italy, Brazil, Austria, Portugal, Ukraine
Fondazione Italiana Linfomi - ETS

Terminated

Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma (GAUDEALIS)

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS
AbbVie

Active, not recruiting

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Lymphoma, Mantle-Cell

Italy
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients (FIL_A-BEGEV)

Relapsed or Refractory Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi - ETS
Janssen-Cilag S.p.A.

Recruiting

Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

DLBCL

Italy
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Not yet recruiting

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma (FIL_POLARDHAP)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

Italy
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Not yet recruiting

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice (FIL_MAB)

Non-Hodgkin Lymphoma, B-cell

Italy
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (FIL_GAZEBO)

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS
Janssen-Cilag S.p.A.

Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (FIL_DALYA)

Plasmablastic Lymphoma

Italy
Fondazione Italiana Linfomi - ETS
Kite, A Gilead Company

Not yet recruiting

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Non-hodgkin Lymphoma,B Cell

Italy
Azienda Ospedaliera Universitaria Integrata Verona
Charite University, Berlin, Germany; Institut National de la Santé Et de la... and other collaborators

Recruiting

Follow-up of Covid-19 Long Term Sequelae

Coronavirus Infections | Covid19 | Coronavirus Disease 2019 | Corona Virus Infection | Coronavirus | SARS-CoV2 Infection | COVID-19 Pneumonia | SARS-CoV-2 Acute Respiratory Disease | SARS (Severe Acute Respiratory Syndrome) | COVID-19 Respiratory Infection | SARS (Disease) | COVID-19 Acute Respiratory Distress... and other conditions

Italy, Belgium, Congo, France, Netherlands, Spain
University of Siena
Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Istituti Ospitalieri... and other collaborators

Recruiting

Genetic Bases of COVID-19 Clinical Variability (GEN-COVID)

COVID-19

Italy

Clinical Trials Sponsored by Fondazione Italiana Sindromi Mielodisplastiche-ETS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations